Wugen nabs $172M to advance memory NK cell platform
Wugen announced it has raised $172 million to support further development of its NK cell platform and to continue ongoing trials for patients with severe acute myelogenous leukemia. Read More
Shape to advance RNA tech platform with $112M in new funding
Shape Therapeutics announced it raised $112 million in financing to continue building its growing portfolio of RNA technologies. Read More
Sana to open new CGT manufacturing facility
Sana Biotechnology has signed a lease to develop a 163,000-sq-ft manufacturing facility in Fremont, CA, to support the manufacture of its late-stage clinical development and early commercial cell and gene therapy (CGT) candidates. Read More
Gene therapy tackles 2 rare childhood diseases 2 different ways
Two new studies point to the efficient use of gene therapy to treat deadly childhood genetic diseases. The first study used direct gene therapy infusion to treat a rare neurodevelopmental disorder, while the second study used prenatal base editing in mouse models as proof of concept for the treatment of genetic diseases. These vastly different approaches show the promise of gene therapy for a variety of devastating diseases. Read More
Strateos launches hybrid SmartLab software platform
Strateos has launched SmartLab, a modular cloud-based software platform designed to assist life science research organizations in connecting onsite research and development labs with remote-controlled facilities. Read More
Prime Medicine launches with gene editing technology
Prime Medicine has launched with $315 million in financing to rapidly advance its prime editing gene editing technology. Read More
Vor, Janssen partner on combination immunotherapy for leukemia
Vor Biopharma is collaborating with Janssen Biotech to develop engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Read More
Inceptor Bio launches FastBack Bio
Inceptor Bio has launched its first portfolio company, Fastback Bio, to accelerate the development of T cell-based therapies targeting difficult to treat solid tumors. Read More
Gyros, Cygnus introduce bioprocess impurity immunoassay solution
Gyros Protein Technologies has introduced its new HEK 293 host cell protein (HCP) immunoassay solution in collaboration with Cygnus Technologies. The Cygnus HEK 293 HCP Assay Reagent Set for Gyrolab is a ready-to-use bioprocess impurity reagent set optimized for use with the Gyrolab automated immunoassay platform. Read More
Sartorius acquires majority stake in CellGenix
Life science company Sartorius has acquired a 51% stake in reagent manufacturer CellGenix through its subsidiary Sartorius Stedim Biotech. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter